Volume 2 / Issue 2
We have incorporated customer feedback to further support your ability to make the best treatment decision for your patients. The report is now streamlined to help make interpretation of results easier.
Three key areas have been streamlined for a clearer and easier-to-interpret report:
<strong>Spotlight On...The Enhanced Invasive Breast Cancer Report</strong>
<strong>Introducing the Enhanced Oncotype DX Breast Report</strong>
<strong>See What’s New with the Enhanced Oncotype DX Breast Reports</strong>
<strong>How the Enhanced Oncotype DX Breast Report Streamlines Information</strong>
<strong>The Oncotype DX Assay for Invasive Breast Cancer and DCIS Featured at the American Society of Breast Surgeons (ASBrS)</strong>
<strong>See Us at the 2014 ASCO Annual Meeting May 30 - June 3, 2014 at McCormick Place in Chicago, Booth #20007</strong>
These changes to the Oncotype DX report are a reflection of Genomic Health’s ongoing commitment to provide the highest quality service and information to breast cancer patients and their physicians.
Christy Russell discusses the enhanced Oncotype DX Breast Report.
Copyright © 2004-2017 Genomic Health, Inc. All Rights Reserved.
The content on this site is intended for U.S. patients and caregivers only.